CEO Dr. David Tomei to discuss research data and potential product applications of non-Invasive Tr-DNA medical testing technology.

The reagents are designed to detect 23 wild type and mutation sequences associated with cystic fibrosis.

Genzyme's BCR-ABL Mutation Analysis test will assist physicians in evaluating resistance to therapy.

The tests identify non-small cell lung cancer patients likely to respond to therapies.

AutovaxID-C reduces the possibility of cross contamination and allows segregation of patient specific vaccine batches.

The diagnostic kit will be used to predict whether an individual is at risk of having a heart attack.

PRIDE is designed to exploit the growing mass of information on how the body's complement of proteins is altered in many disease states.